Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances

American Journal Geriatric Pharmacotherapy

Volumn 3, Issue 2, 2005, Pages 87-91

  Bies, Robert R ^a,b   Mulsant, Benoit H ^a,c   Rosen, Jules ^a   Huber, Kimberly A ^a   Wilson, Nicole L ^a   Kirshner, Margaret A ^a   Pollock, Bruce G ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Geriatric psychiatry; Population pharmacokinetics; Risperidone

Indexed keywords

AMLODIPINE; AMOXICILLIN; ATENOLOL; AZITHROMYCIN; BISACODYL; BUMETANIDE; CALCIUM; CEFALEXIN; CELECOXIB; CLONIDINE; CONJUGATED ESTROGEN; DIGOXIN; DILTIAZEM; DOCUSATE SODIUM; FUROSEMIDE; GLIBENCLAMIDE; GLIPIZIDE; HYDROCHLOROTHIAZIDE; IBUPROFEN; IRON; LANSOPRAZOLE; LEVOTHYROXINE; LISINOPRIL; LORAZEPAM; METFORMIN; METOPROLOL; PALIPERIDONE; PARACETAMOL; RISPERIDONE; UNINDEXED DRUG;

AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXPOSURE; HOSPITAL PATIENT; HUMAN; MENTAL HOSPITAL; PILOT STUDY; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; CLINICAL TRIALS; DEMENTIA; FEMALE; HOME CARE SERVICES; HOSPITALIZATION; HUMANS; MALE; MODELS, BIOLOGICAL; RISPERIDONE;

EID: 23944446777     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2005.07.002     Document Type: Article

References (11)

1. Pollock BG Mulsant BH Rosen J et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients Am J Psychiatry 159 2002 460-465
2. FDA public health advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. Available at: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm. Accessed April 26, 2005.
3. Tariot P Profenno LA Ismail MS Efficacy of atypical antipsychotics in elderly patients with dementia J Clin Psychiatry 65 Suppl 11 2004 11-15
4. Katz IR Jeste DV Mintzer JE et al. for the Risperidone Study Group Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial J Clin Psychiatry 60 1999 107-115
5. Bies RR Feng Y Lotrich FE et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects J Clin Pharmacol 44 2004 1352-1359
6. Bies RR Gastonguay MR Coley KC et al. Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques Am J Geriatr Psychiatry 10 2002 696-705
7. Lu J Gries JM Verotta D Sheiner LB Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance J Pharmacokinet Pharmacodyn 28 2001 343-362
8. Jonsson EN Wade JR Almqvist G Karlsson MO Discrimination between rival dosing histories Pharm Res 14 1997 984-991
9. Brundage RC Yong FH Fenton T et al. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy Antimicrob Agents Chemother 48 2004 979-984
10. Maxwell RA Sweet RA Mulsant BH et al. Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjects J Geriatr Psychiatry Neurol 15 2002 77-81
11. Beal SL Ways to fit a PK model with some data below the quantification limit [published correction appears in J Pharmacokinet Pharmacodyn. 2002;29:309] J Pharmacokinet Pharmacodyn 28 2001 481-504